KR20190032479A - 결합능을 갖는 융합 단백질을 포함하는 세포외 소포의 용도 - Google Patents

결합능을 갖는 융합 단백질을 포함하는 세포외 소포의 용도 Download PDF

Info

Publication number
KR20190032479A
KR20190032479A KR1020197005093A KR20197005093A KR20190032479A KR 20190032479 A KR20190032479 A KR 20190032479A KR 1020197005093 A KR1020197005093 A KR 1020197005093A KR 20197005093 A KR20197005093 A KR 20197005093A KR 20190032479 A KR20190032479 A KR 20190032479A
Authority
KR
South Korea
Prior art keywords
leu
ser
gly
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197005093A
Other languages
English (en)
Korean (ko)
Inventor
안드레 괴르겐스
다누 굽타
오스카르 위클란데르
Original Assignee
에복스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에복스 테라퓨틱스 리미티드 filed Critical 에복스 테라퓨틱스 리미티드
Publication of KR20190032479A publication Critical patent/KR20190032479A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020197005093A 2016-07-21 2017-07-21 결합능을 갖는 융합 단백질을 포함하는 세포외 소포의 용도 Withdrawn KR20190032479A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1612643.5A GB2552473A (en) 2016-07-21 2016-07-21 Surface decoration of extracellular vesicles
GB1612643.5 2016-07-21
PCT/EP2017/068486 WO2018015539A1 (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity

Publications (1)

Publication Number Publication Date
KR20190032479A true KR20190032479A (ko) 2019-03-27

Family

ID=56894359

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197005093A Withdrawn KR20190032479A (ko) 2016-07-21 2017-07-21 결합능을 갖는 융합 단백질을 포함하는 세포외 소포의 용도
KR1020197005096A Active KR102636776B1 (ko) 2016-07-21 2017-07-21 결합능을 갖는 융합 단백질을 포함하는 세포외 소포

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197005096A Active KR102636776B1 (ko) 2016-07-21 2017-07-21 결합능을 갖는 융합 단백질을 포함하는 세포외 소포

Country Status (12)

Country Link
US (3) US11236143B2 (https=)
EP (3) EP3487528B1 (https=)
JP (4) JP7140743B2 (https=)
KR (2) KR20190032479A (https=)
CN (2) CN109689098A (https=)
AU (2) AU2017299214A1 (https=)
BR (2) BR112019001099A2 (https=)
CA (2) CA3031183A1 (https=)
GB (1) GB2552473A (https=)
MX (2) MX2019000863A (https=)
SG (4) SG11201811152YA (https=)
WO (2) WO2018015539A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230039787A (ko) * 2021-09-08 2023-03-21 주식회사 꿈랩 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼
WO2024225825A1 (ko) * 2023-04-26 2024-10-31 주식회사 인엑소플랫 면역글로불린 fc 영역 또는 이의 변이체를 포함하는 재조합 세포외 소포체 및 이를 이용한 세포외 소포체의 분리 방법

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008697A2 (pt) 2010-09-24 2016-06-21 Massachusetts Inst Technology géis nanoestruturados capazes de liberação controlada de agentes encapsulados
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
JP2021520352A (ja) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス， インコーポレイテッド 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法
TWI770396B (zh) * 2018-06-28 2022-07-11 中央研究院 合成多肽及其用途
KR102917499B1 (ko) 2018-07-20 2026-01-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법
GB201812992D0 (en) 2018-08-09 2018-09-26 Univ Greenwich Liposomes
SG11202100864VA (en) 2018-08-14 2021-02-25 Evercyte Gmbh Target-specific extracellular vesicles
CN108998402B (zh) * 2018-08-28 2020-05-29 江南大学 一种重组枯草芽孢杆菌及其构建方法与应用
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
BR112021007286A2 (pt) 2018-10-19 2021-07-27 Ohio State Innovation Foundation células furtivas terapêuticas nanoprojetadas
CN113286826A (zh) * 2018-10-19 2021-08-20 俄亥俄州国家创新基金会 用于针对髓源性抑制细胞的靶向治疗的细胞外囊泡
BR112021007285A2 (pt) 2018-10-19 2021-07-27 Ohio State Innovation Foundation nanocarreadores para terapia de inflamação pulmonar
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
CN113272426A (zh) * 2018-11-16 2021-08-17 医福斯治疗有限公司 用于尿素循环蛋白和核酸的替代的细胞外囊泡
BR112021012647A2 (pt) * 2018-12-27 2021-09-14 Akeso Biopharma, Inc Anticorpo, polipeptídeo isolado, polinucleotídeo isolado, vetor, célula hospedeira, métodos para preparar o anticorpo e para a prevenção e/ou tratamento e/ou tratamento adjuvante e/ou diagnóstico de uma doença, conjugado de anticorpo, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, kit, usos do anticorpo, método in vivo ou in vitro, célula de hibridoma e anticorpo monoclonal
CA3128386A1 (en) * 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
EP3965829A4 (en) * 2019-05-06 2023-05-24 Malcolm, Thomas ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
WO2020252455A1 (en) * 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020249757A1 (en) * 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP3986429A4 (en) * 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. PLATFORMS, COMPOSITIONS, AND METHODS OF ADMINISTRATION OF THERAPEUTICS
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
WO2021045501A1 (ko) * 2019-09-02 2021-03-11 경북대학교 산학협력단 Il-2 표면 발현 세포외 소포체를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
JP2023512562A (ja) 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
WO2021211460A1 (en) * 2020-04-13 2021-10-21 City Of Hope Cell-receptor targeted exosomes
CN111544453B (zh) * 2020-04-27 2021-01-22 高连如 一种包含三种血管再生属性的混合干细胞注射液及其制备方法
CN111560352B (zh) * 2020-06-02 2023-03-24 新疆农业大学 一种病毒样囊泡及其制备方法和应用
CN111905105B (zh) * 2020-07-02 2023-05-05 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
CN112111513A (zh) * 2020-07-17 2020-12-22 深圳市第二人民医院 基于外泌体平台的新冠病毒疫苗制备方法
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CN113967254B (zh) * 2020-08-04 2022-08-12 华南理工大学 用于多特异性抗体递送的细胞膜包覆型纳米适配子及应用
JP2023536665A (ja) * 2020-08-05 2023-08-28 オハイオ・ステイト・イノベーション・ファウンデーション アダプターポリペプチドおよびその使用方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
WO2022149779A1 (ko) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR102252325B1 (ko) * 2021-01-14 2021-05-14 이장호 태아 유래 태초 면역글로불린을 포함하는 세포외소포의 제조방법
WO2022158836A1 (ko) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
US20240218046A1 (en) * 2021-04-14 2024-07-04 Anjarium Biosciences Ag Fc-derived polypeptides
JP2024514157A (ja) * 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー 薬物送達のためのペプチド、ナノ小胞、及びその使用
CA3217654A1 (en) * 2021-04-23 2022-10-27 Spot Biosystems Ltd. Extracellular vesicles loaded with biomolecules
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
EP4355304A4 (en) * 2021-06-17 2025-04-30 Malcolm, Thomas PERSONALIZED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCERS, INHERITED DISEASES AND INFECTIOUS DISEASES
CN115770302A (zh) * 2021-08-13 2023-03-10 南京大学 一种rna递送系统及其应用
CN113599516B (zh) * 2021-08-16 2022-02-18 上海蒙彼利生物技术有限公司 制备外泌体方法及其药物组合物在组织修复中的应用
CN113897387B (zh) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用
DK4190349T3 (da) * 2021-12-03 2025-04-14 Univ China Medical Produktion af exosomer og anvendelse heraf
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
CN114236113B (zh) * 2021-12-21 2023-07-21 南京农业大学 一种2,4-滴的即用型免疫传感器
WO2023133425A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
EP4505178A4 (en) * 2022-04-07 2026-04-29 Univ Michigan Regents METHODS AND DEVICES FOR SCREENING EXTRACELLULAR VESICLES
WO2024064748A2 (en) * 2022-09-20 2024-03-28 North Carolina State University Compositions and methods related to exosomal delivery of therapeutic agents
CN116179582A (zh) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用
CN117802045A (zh) * 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
CN115873905A (zh) * 2022-11-15 2023-03-31 重庆医科大学附属儿童医院 一种gd2纳米抗体靶向修饰的类外泌体的新型药物载体的制备方法
KR102929157B1 (ko) 2023-03-08 2026-02-23 차이나 메디칼 유니버시티 엑소좀의 생산 및 이의 용도
WO2024225847A1 (ko) * 2023-04-28 2024-10-31 연세대학교 산학협력단 유방암 유래 엑소좀 또는 세포외 소포체 분리 방법
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN119120376A (zh) * 2023-07-10 2024-12-13 浙江大学医学院附属第一医院 一种用于清除致病抗体的嵌合基因工程化纳米囊泡及其制备方法、应用
WO2025068572A2 (en) 2023-09-29 2025-04-03 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs
WO2025102257A1 (zh) * 2023-11-15 2025-05-22 深圳先进技术研究院 一种靶向子宫工程化细胞外囊泡的制备方法及其应用
CN121100135A (zh) * 2024-04-18 2025-12-09 苏州鲲石一号生物科技有限公司 Gas6融合蛋白及其制备方法与应用
CN118725135B (zh) * 2024-09-02 2025-02-07 中国科学院苏州纳米技术与纳米仿生研究所 外泌体的改造方法
CN119019494B (zh) * 2024-10-28 2025-02-07 广州飞来爱生命科技有限公司 一种治疗心梗的脐带间充质干细胞及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059643A2 (en) * 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP2007295929A (ja) * 2006-04-05 2007-11-15 Geno Membrane:Kk イヌＢｓｅｐ遺伝子
CA2747020A1 (en) * 2007-08-30 2009-03-05 Virexx Medical Corp. Antigenic compositions and use of same in the targeted delivery of nucleic acids
JP2010540466A (ja) 2007-09-24 2010-12-24 ザ ユニバーシティ オブ クイーンズランド 分子送達ベシクル
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
CA2827443C (en) 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
EP3057662A4 (en) 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230039787A (ko) * 2021-09-08 2023-03-21 주식회사 꿈랩 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼
WO2024225825A1 (ko) * 2023-04-26 2024-10-31 주식회사 인엑소플랫 면역글로불린 fc 영역 또는 이의 변이체를 포함하는 재조합 세포외 소포체 및 이를 이용한 세포외 소포체의 분리 방법

Also Published As

Publication number Publication date
BR112019001108A2 (pt) 2019-07-02
MX2019000861A (es) 2019-09-04
JP2019524745A (ja) 2019-09-05
EP3487528B1 (en) 2023-08-30
WO2018015535A1 (en) 2018-01-25
CA3031186A1 (en) 2018-01-25
JP7254016B2 (ja) 2023-04-07
WO2018015539A1 (en) 2018-01-25
KR20190032480A (ko) 2019-03-27
JP7140743B2 (ja) 2022-09-21
AU2017299214A1 (en) 2019-02-07
US20200109183A1 (en) 2020-04-09
JP2023026440A (ja) 2023-02-24
US11236143B2 (en) 2022-02-01
EP4299137A3 (en) 2024-04-10
SG10202100598RA (en) 2021-02-25
SG11201811151PA (en) 2019-01-30
SG11201811152YA (en) 2019-01-30
US20230181757A1 (en) 2023-06-15
JP2022117998A (ja) 2022-08-12
EP3487528A1 (en) 2019-05-29
US20220098267A1 (en) 2022-03-31
EP3487529A1 (en) 2019-05-29
CN109689097B (zh) 2023-01-03
CN109689097A (zh) 2019-04-26
KR102636776B1 (ko) 2024-02-15
AU2017300035A1 (en) 2019-02-07
JP2019523407A (ja) 2019-08-22
GB201612643D0 (en) 2016-09-07
GB2552473A (en) 2018-01-31
BR112019001099A2 (pt) 2019-06-25
EP4299137A2 (en) 2024-01-03
CA3031183A1 (en) 2018-01-25
CN109689098A (zh) 2019-04-26
MX2019000863A (es) 2019-09-04
SG10202100597TA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
KR20190032479A (ko) 결합능을 갖는 융합 단백질을 포함하는 세포외 소포의 용도
CN111344012B (zh) 工程改造的细胞外囊泡的亲和纯化
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
CN116731188B (zh) 抗pd-l1和vegf双特异性抗体及其应用
AU2020245375A1 (en) Targeted active gene editing agent and methods of use
JP2021533834A (ja) 標的特異的細胞外小胞
CN115043940B (zh) 抗人血清白蛋白抗体及其应用
KR20240026182A (ko) 신규 단일 도메인 항원 결합 분자 및 이의 용도
CN117396507A (zh) 抗bcam抗体或其抗原结合片段
US20200330591A1 (en) Treatment
CN116023497B (zh) 抗ddr1抗体及其用途
US20260116970A1 (en) Novel sirp nanobodies
EP4685159A1 (en) Single domain antibodies to cd34 suitable for targeting hematopoietic stem cells
TW202613178A (zh) 抗cll-1的奈米抗體及其應用
CA2977888C (en) Antibody which binds lrg1 and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200720

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210714

WITB Written withdrawal of application